Executive Management


Donna has 30+ years of healthcare experience, beginning as critical care nurse, and migrating to operating and senior management in hospital, physician group practices, and then diagnostic industry positions.

She was 8+ years with Baxter in senior (group) executive positions in business development, sales and marketing of clinical products aimed at improving care and reducing health care costs. She served in senior management roles for 10 diagnostic companies.

Key leadership in two company exits

Recognized leader in Cardiovascular Diagnostics, changing clinical practice in this space
Formed Virginia Life Sciences Investments, Inc. and led Series A investment in ImmunArray, original home of broad portfolio of biomarkers for Neurological Disease Diagnosis and Monitoring

Steve joined ImmunArray in January 2013 and transitioned part time to BBS as the company was being spun out of ImmunArray.

He will continue to fill this role going forward. He brings more than 30 years of R&D and operations experience in the biotechnology, pharmaceutical and chemical industries to the company.

His expertise in small molecule and recombinant protein drug development includes process development, manufacturing, quality regulatory submissions, strategic planning and financial analysis. At Insmed, he successfully led the processes leading to the regulatory submission and FDA approval of rhIGF-I/rhIGFBP-3. At Boehringer Ingelheim and Hoechst Celanese, he developed, optimized and implemented growth strategies resulting in more than $50,000,000 in annual cost savings and new business. Steve holds a B.S. in Chemical Engineering from The Georgia Institute of Technology and a MBA from The College of William and Mary.

Nathan has over 20+ years of experience in Quality Assurance, Regulatory Affairs, Compliance and Project Management with medical devices, in-vitro diagnostics, pharmaceutical and biologics products.

During this time, Nathan has lead multiple organizations in the domestic and international clearance and expansion of product lines. Prior to joining ImmunArray USA, Inc. in June 2016, Nathan held the position of Sr. Director of Quality and Compliance at a medical device start-up organization and has been part of the initial TBI team in quality, regulatory and program development since then. He is currently a shared resource with the majority of his time spent on BrainBox Solutions.

Tim has over 20 years of experience in assay development, clinical research, genomics and microarray technologies. In his career in neuroscience and cancer, he has spearheaded international research consortia.

Tim received his Bachelors of Science in Biology at the University of Vermont, his Master’s in Neuroscience and his PhD in Neuropathology from King’s College, University of London. His PhD thesis work and further post-doctoral training, were performed in the Department of Neurosurgery at VCU where he assumed a faculty position. Since joining ImmunArray in 2015, he has designed and directed the research and development efforts that have taken the TBI portfolio from licensed IP to technically sound assays that provide clinical discrimination. In directing the research program, he has organized the publication strategy, has been the main author and presenter of company data to national and international audiences.

Scientific Advisory Board


The Scientific Advisory Board meets with the Management team, as a group, on a regularly scheduled basis. They are very active participants in each and every clinical and business decision. Not just occasional advisors, they are integral to our commitment to set the standard of care in TBI diagnosis and management of patients in this large and challenging field.


Dr. Okonkwo is executive vice chair for clinical operations and is director of neurotrauma, director of scoliosis and spinal deformity at UPMC Presbyterian. He is also professor and clinical director of the Brain Trauma Research Center of the University of Pittsburgh.

Dr. Okonkwo’s clinical interests are traumatic injuries to the brain and spine as well as scoliosis and spinal deformity. His research endeavors involve developing advanced neuroimaging modalities and novel therapeutic interventions for brain and spinal cord injury. Dr. Okonkwo is the principal investigator of a nationally funded clinical core to study the pathophysiology of traumatic brain injury.

He is also principal investigator of several ongoing clinical studies in Neurotrauma in Pittsburgh. He is also PI and Clinical Core Leader and Study Site Leader for TRACK-TBI the NINDS-funded, multicenter Transforming Research and Clinical Knowledge in Brain Injury study.

Dr. Frank Peacock is Professor of Emergency Medicine, Associate Chief of Emergency Medicine and Research Director for Emergency Medicine at Baylor College of Medicine. He is also the immediate past chief medical officer and prior president of the Society of Cardiovascular Patient Care.

Dr. Peacock has and continues to serve as PI or co-PI for many high profile national and international clinical trials such as PRONTO, ADHERE-EM, IMPACT, CHOPIN, CLUE, FASTTRACK and TRUE-HF. His clinical interests and research focus include acute coronary syndrome, acute heart failure, Traumatic Brain Injury, biomarkers, improvements in emergency medical care, and more rapid patient disposition.

Dr. Peacock received his medical degree from Wayne State University Medical School and completed his Emergency Medicine training at William Beaumont Hospital, Detroit, Mich.

A world-leading expert in traumatic brain injury, Diaz-Arrastia is the Presidential Professor of Neurology in Penn’s Perelman School of Medicine.

His most recent work explores using MRI, functional MRI and PET scanning to characterize the multiple complex mechanisms involved in traumatic injury to the brain, as well as combining imaging, genomic and tissue biomarkers to better predict patient outcomes after traumatic brain injuries and to develop novel therapies.

Diaz-Arrastia earned an M.D. in 1988 and Ph.D. in biochemistry in 1986 from Baylor College of Medicine and a B.A. magna cum laude in biochemistry in 1979 from Rice University. From 1989 to 1992, he was a resident in neurology at Columbia-Presbyterian Medical Center, following a one-year internship in internal medicine at Beth Israel Hospital/Harvard Medical School.

Allison Kumar has over 15 years of combined experience with the US Food and Drug Administration and biotechnology industry. Allison is considered a key opinion leader on numerous scientific and regulatory policy issues, including the complex areas of combination products, in vitro and companion diagnostics and biomarker qualification.

Allison currently combines her deep institutional knowledge with innovative approaches to help companies successfully communicate product information to FDA throughout the total product life cycle. Leveraging her years of reviewer experience and broad FDA exposure, she develops actionable premarket strategies to guide programs through successful submission. During her 10-year tenure at FDA, Allison held positions as a Sr. Program Manager in the Office of the Center Director at the FDA’s Center for Devices and Radiological Health (CDRH) and as a Sr. Pre-market Reviewer in the CDRH Office of Device Evaluation.

Dr. Atabaki is Professor of Pediatrics and Emergency Medicine at the George Washington University and Children’s National Health System. Dr. Atabaki is the Medical Director of Informatics and Associate Medical Director of Telemedicine at Children’s National.

Dr. Atabaki’s area of research expertise is in concussion and health informatics and she has been principal investigator on development of clinical decision rules for decreasing unnecessary CT scans, assessment of concussions and medical therapies for prophylaxis of post-traumatic seizure.

Dr. Atabaki received the National Heroes Award for Research, awarded by the Maternal Child Health Bureau, for her leadership in research to reduce unnecessary CT scans and radiation in children with traumatic brain injury. She is the recipient of the prestigious Ellis Island Medal of Honor for her work in advocacy, research and clinical care for children.

Dr. Wu is a Professor of Laboratory Medicine at the UCSF School of Medicine and is the chief of the clinical chemistry and toxicology laboratories at San Francisco General Hospital. In this capacity, his clinical and research laboratory conducts testing for routine analytes in blood, urine and cerebral spinal fluid for electrolytes, metabolites, hormones, proteins, and biomarkers.

His particular area of interest is in cardiac biomarkers for acute cardiac diseases (troponin, B-type natriuretic peptide, and novel biomarkers of ACS and heart failure). He has been expanding his work in biomarkers in Brain Injury over the past 2 years as well. An additional primary area of research is focused on “personalized therapeutics,” i.e., the use of biomarkers to determine proper selection and dosing of drugs to maximize efficacy and minimize adverse reactions. His research lab also conducts research on point-of-care testing devices.

Board of Directors


Donna has 30+ years of healthcare experience, beginning as critical care nurse, and migrating to operating and senior management in hospital, physician group practices, and then diagnostic industry positions.

She was 8+ years with Baxter in senior (group) executive positions in business development, sales and marketing of clinical products aimed at improving care and reducing health care costs. She served in senior management roles for 10 diagnostic companies;

Key leadership in two company exits

Recognized leader in Cardiovascular Diagnostics, changing clinical practice in this space
Formed Virginia Life Sciences Investments, Inc. and led Series A investment in ImmunArray, original home of broad portfolio of biomarkers for Neurological Disease Diagnosis and Monitoring.

Marc is co-founder and Managing Partner of BioVentures Investors. He brings well over 30 years of managerial and investment experience in the healthcare sector.

Marc is a member of the Harvard Medical School Advisory Council on Discovery, serves as Chairman Emeritus of the Harvard Varsity Club and is a member of the Board of Directors for both Step by Step Supportive Services and the Richi Childhood Cancer Foundation. Marc currently serves on the Board of Directors for Endotronix, Verax Biomedical, POC Medical, Cardiosolutions, HydroCision, sGC Pharma and Rachiotek

Bob is the chairman of the board for Owens & Minor Inc. He is also an advisor to New Richmond Ventures and managing partner of Pinnacle Ventures LLC and Sledd Properties, a family commercial real estate company.

Previously, he was with Performance Food Group, a company which he co-founded in 1987 and where he served in the roles of President, CEO and Chairman until the company’s acquisition by and merger with Vistar and Roma Food in 2008.

Bob is on the board of Owens & Minor Inc., SCP Pool Corporation, Universal Corporation, and Bon Secours Health System, Richmond. He was also senior economic advisor to Virginia Governor’s office from 2010-2013. Long active in community affairs, Bob currently serves on the board of VCU School of Business Foundation and Homeward’s Board of Advocates. Past board service includes the Management Roundtable and nonprofits such as Venture Richmond and Better Housing Coalition.

Key Collaborations & Partnerships